Table 1.
Patients’ characteristics
| Patients n | 10 |
|---|---|
| Median age (range)—yrs | 59 (31–74) |
| Age ≥ 60 yrs—no. (%) | 4 (40) |
| Gender—male (%) / female (%) | 6 (60)/4 (40) |
| Diagnosis | |
| Diffuse large B-cell lymphoma | 8 (80) |
| Transformed follicular lymphoma | 2 (20) |
| Disease stage (at diagnosis) | |
| IA | 1 (10) |
| IIA | 2 (20) |
| IIE | 1 (10) |
| IIIA | 3 (30) |
| IIIB | 1 (10) |
| IVA | 2 (20) |
| International prognostic index (at diagnosis) | 1 (0–2) |
| 0 | 3 (30) |
| 1 | 3 (30) |
| 2 | 4 (40) |
| No. of previous lines of antineoplastic therapy—no. (%) | |
| 2 | 1 (10) |
| 3 | 1 (10) |
| 4 | 3 (30) |
| ≥ 5 | 5 (50) |
| Previous autologous hematopoietic stem cell transplantation—no. (%) | 5 (50) |
| Relapsed/Refractory DLBCL—no. (%) | 10 (100) |
| Median time from diagnosis until CAR-T therapy (range)—months | 23 (11–197) |
| Median CAR-T cell dose (range)—cells × 10^8/kg BW | 2.8 (1–0-3.50) |
| CRS—no. (%) | 4 (40) |
| Grade 1–2 | 3 (30) |
| Grade ≥ 3 | 1 (10) |
| ICAN—no. (%) | 4 (40) |
| Grade 1 | 1 (10) |
| Grade 2 | 3 (30) |
| Treatment on ICU | 3 (30) |
| Tocilizumab | 2 (20) |
| Steroids | 3 (30) |
| Median follow-up post CAR-T cell therapy (range)—months | 4 (0–7) |
| Progressive disease at last follow-up after CAR-T-cell therapy—no. (%) | 7 (70) |
| Alive at last follow-up after CAR-T-cell therapy—no. (%) | 6 (60) |
| Death due to progressive disease | 3 (30) |